H1

H1
Saluggia (Italy), July 27, 2023 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), examined and approved the Half-Year Financial Report at June 30, 2023.
Q1

Q1
Saluggia (Italy), May 9, 2023 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), examined and approved the consolidated economic and financial results of the first quarter 2023.
FY

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE
Saluggia (Italy), March 27, 2023 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2022.
9M

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards
The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, today examined and approved the consolidated economic and financial results of the first 9 months of 2022.
H1

Strong revenues growth in the First Half of 2022
Saluggia (Italy), August 3, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, today examined and approved the Half-Year Financial Report at June 30, 2022.

Q1

Strong growth in revenues and cash flow generation in Q1 2022
Saluggia (Italy), May 6, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, meeting today examined and approved the consolidated economic and financial results for Q1 2022.

FY

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
Saluggia (Italy), March 16, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2021

9M

DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021
Saluggia (Italy), November 11, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, reviewed and approved 9M 2021 consolidated economic and financial results.

H1

DiaSorin: Revenues and Profitability continue upward momentum in H1 2021, with Guidance raised following the acquisition of Luminex
Saluggia (Italy), July 30, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), today examined and approved the Half-Year Financial Report at June 30, 2021

Q1

DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021
Saluggia (Italy), May 14, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, examined and approved the Q1’21 consolidated economic and financial results.

FY

DiaSorin – Revenues, Profitability and Cash Flow Generation hit record highs in 2020
Saluggia (Italy), March 11, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2020.

9M

North America growth drives up revenues and profitability in the first 9 months of 2020, with strong business acceleration in the third Quarter
Saluggia (Italy), November 11, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, reviewed and approved 9M 2020 consolidated economic and financial results.

H1

North America business growth drives Group revenues and profitability in the first half of 2020
Saluggia (Italy), July 30, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, reviewed and approved H1 2020 consolidated economic and financial results.

Q1

DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic
Saluggia (Italy), May 13, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, examined and approved the Q1’20 consolidated economic and financial results

FY

DiaSorin - Cash flow generation and net profit hit record highs in 2019
Saluggia (Italy), March 11, 2020 – The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2019

9M

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019
Saluggia (Italy), November 6, 2019 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved 9M 2019 consolidated economic and financial results.

H1

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.
Saluggia (Italy), July 31, 2019 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, meeting today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, reviewed and approved H1 2019 consolidated economic and financial results.

Q1

DiaSorin Group reports growth in profitabilitity and strong free cash flow generation in the first quarter 2019
Saluggia (Italy), May 9, 2019 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, meeting today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, reviewed and approved Q1 2019 consolidated economic and financial results.

FY

Growth in revenues, profitability and net profit in 2018
Saluggia (Italy), March 14, 2019 – The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), global leader in the research, production and marketing of diagnostic tests, meeting today: examined and approved the Group’s Consolidated Financial Statements at December 31, 2018, examined and approved the Company’s Draft Statutory Financial Statements at December 31, 2018.

9M

Growth in revenues and net profit in the first nine months of 2018 for the DiaSorin Group
Saluggia (Italy), November 7, 2018 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved the consolidated economic and financial results of the first 9 months of 2018.

H1

Strong increase in net profit and free cash flow
Saluggia (Italy), August 2, 2018 – The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved the consolidated economic and financial results of H1’18.

Q1

Growth in revenues and profitability in the first quarter 2018
Saluggia (Italy), May 8, 2018 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved the consolidated economic and financial results of Q1’18.

FY

Growth in revenues, profitability and net profit in 2017
Saluggia (Italy), March 7, 2018 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA) examined and approved the Group’s Consolidated Financial Statements at December 31, 2017.
Proposed ordinary dividend of € 0.85 per share and special dividend of € 1.80 per share. Revenues and EBITDA guidance achieved.

FY

DiaSorin: Net Profit and Cash Generation reached record highs in 2016, driven by growth in Revenues and Profitability
Saluggia (Italy), March 8, 2017 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2016

FY

Net profit and cash generation reached record highs
Saluggia (Italy), March 9, 2016 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, meeting today, examined and approved the Group’s Consolidated Financial Statements at December 31, 2015 and proposed the distribution of a dividend of 35,748,899.55 euros, equal to € 0.65 on each share outstanding.

FY

The Board of Directors of DiaSorin S.p.A. approves the full year 2014 results reporting strong cash flow and solid net financial position following the growth in revenues and profit
Saluggia, March 3, 2015 - The Board of Directors of DiaSorin S.p.A approved the Group’s Consolidated Financial Statements at December 31, 2014 and the distribution of a dividend of 32,929,954.20 euros, equal to € 0.60 on each share outstanding.
